Dot Compliance Secures $17M in Series B Extension Funding
April 15, 2024, 9:34 pm
Location: United States, Arizona, Phoenix
Employees: 51-200
Founded date: 2007
Total raised: $40.5M
Phoenix-based Dot Compliance, a leading provider of AI-powered quality management systems for compliance, recently closed a $17 million Series B extension funding round. This latest funding brings their total investment to a solid $50 million, showing strong investor confidence in the company's innovative solutions.
Dot Compliance's AI solutions offer a vendor-neutral eQMS platform that covers a range of compliance needs, including document, change, and supplier quality management. Their solutions address key compliance regulations and standards such as FDA 21 CFR Part II, FDA 21 CFR Part 820, and EU GMP Annex II.
The company plans to use the newly acquired funds to further enhance their AI solutions, drive customer acquisition, and foster innovation. Mickey Landkof, the general manager and global VP of sales at Dot Compliance, expressed excitement about the company's growth and evolution, highlighting their commitment to innovation and customer support.
Founded in 2015, Dot Compliance introduced its generative AI eQMS solution, Dottie AI, in 2023. Competitors in the eQMS space include Intellect and Qualio, both offering AI-driven solutions to streamline quality and safety processes.
Dot Compliance's success in securing this funding reflects the growing demand for AI-driven compliance solutions in the healthcare industry. With a focus on data-driven innovation, the company is poised to continue leading the way in transforming compliance processes for life sciences organizations.
Overall, Dot Compliance's latest funding round underscores their commitment to driving innovation and delivering cutting-edge solutions to meet the evolving needs of the compliance landscape. With a strong foundation in AI technology, the company is well-positioned to make a significant impact in the healthcare industry and beyond.
Dot Compliance's AI solutions offer a vendor-neutral eQMS platform that covers a range of compliance needs, including document, change, and supplier quality management. Their solutions address key compliance regulations and standards such as FDA 21 CFR Part II, FDA 21 CFR Part 820, and EU GMP Annex II.
The company plans to use the newly acquired funds to further enhance their AI solutions, drive customer acquisition, and foster innovation. Mickey Landkof, the general manager and global VP of sales at Dot Compliance, expressed excitement about the company's growth and evolution, highlighting their commitment to innovation and customer support.
Founded in 2015, Dot Compliance introduced its generative AI eQMS solution, Dottie AI, in 2023. Competitors in the eQMS space include Intellect and Qualio, both offering AI-driven solutions to streamline quality and safety processes.
Dot Compliance's success in securing this funding reflects the growing demand for AI-driven compliance solutions in the healthcare industry. With a focus on data-driven innovation, the company is poised to continue leading the way in transforming compliance processes for life sciences organizations.
Overall, Dot Compliance's latest funding round underscores their commitment to driving innovation and delivering cutting-edge solutions to meet the evolving needs of the compliance landscape. With a strong foundation in AI technology, the company is well-positioned to make a significant impact in the healthcare industry and beyond.